United Kingdom - English - myHealthbox

chiesi limited - salbutamol sulfate - modified release capsules, hard - 9.60mg - selective beta2 -adrenoceptor agonists for systemic use - continuous symptomatic treatment of asthma and other types of reversible obstructive airways disease

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult kidney or liver allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - deferiprone - beta-thalassemia; iron overload - all other therapeutic products - ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antithrombotic agents - kengrexal, co-administered with acetylsalicylic acid (asa), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (pci) who have not received an oral p2y12 inhibitor prior to the pci procedure and in whom oral therapy with p2y12 inhibitors is not feasible or desirable.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - mercaptamine bitartrate - cystinosis - other alimentary tract and metabolism products, - procysbi is indicated for the treatment of proven nephropathic cystinosis. cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici spa - caffeine citrate - apnea - psychoanaleptics, - treatment of primary apnoea of premature newborns.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - velmanase alfa - alpha-mannosidosis - other alimentary tract and metabolism products, - treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.,

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi farmaceutici s.p.a. - beclometasone dipropionate; formoterol fumarate dihydrate - pressurised inhalation, solution - 100 /6 µg/µg - formoterol and beclometasone